JP2010090130A5 - - Google Patents

Download PDF

Info

Publication number
JP2010090130A5
JP2010090130A5 JP2009263603A JP2009263603A JP2010090130A5 JP 2010090130 A5 JP2010090130 A5 JP 2010090130A5 JP 2009263603 A JP2009263603 A JP 2009263603A JP 2009263603 A JP2009263603 A JP 2009263603A JP 2010090130 A5 JP2010090130 A5 JP 2010090130A5
Authority
JP
Japan
Prior art keywords
cys
arg
phe
seq
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009263603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010090130A (ja
JP5889513B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010090130A publication Critical patent/JP2010090130A/ja
Publication of JP2010090130A5 publication Critical patent/JP2010090130A5/ja
Application granted granted Critical
Publication of JP5889513B2 publication Critical patent/JP5889513B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2009263603A 2005-07-08 2009-11-19 メラノコルチン受容体リガンド Expired - Lifetime JP5889513B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US60/697,779 2005-07-08
US74885005P 2005-12-09 2005-12-09
US60/748,850 2005-12-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008520417A Division JP4734411B2 (ja) 2005-07-08 2006-07-10 メラノコルチン受容体リガンド

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013165312A Division JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Division JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Publications (3)

Publication Number Publication Date
JP2010090130A JP2010090130A (ja) 2010-04-22
JP2010090130A5 true JP2010090130A5 (cg-RX-API-DMAC7.html) 2011-06-23
JP5889513B2 JP5889513B2 (ja) 2016-03-22

Family

ID=37637790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008520417A Expired - Lifetime JP4734411B2 (ja) 2005-07-08 2006-07-10 メラノコルチン受容体リガンド
JP2009263603A Expired - Lifetime JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Expired - Lifetime JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008520417A Expired - Lifetime JP4734411B2 (ja) 2005-07-08 2006-07-10 メラノコルチン受容体リガンド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Expired - Lifetime JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Country Status (21)

Country Link
US (9) US8039435B2 (cg-RX-API-DMAC7.html)
EP (6) EP2548568B1 (cg-RX-API-DMAC7.html)
JP (4) JP4734411B2 (cg-RX-API-DMAC7.html)
KR (2) KR101232201B1 (cg-RX-API-DMAC7.html)
CN (5) CN119119190A (cg-RX-API-DMAC7.html)
AU (2) AU2006269261B2 (cg-RX-API-DMAC7.html)
BE (1) BE2021C557I2 (cg-RX-API-DMAC7.html)
CA (4) CA2793119C (cg-RX-API-DMAC7.html)
DK (4) DK3354273T3 (cg-RX-API-DMAC7.html)
ES (4) ES2663916T3 (cg-RX-API-DMAC7.html)
FR (1) FR21C1060I2 (cg-RX-API-DMAC7.html)
HU (4) HUE031731T2 (cg-RX-API-DMAC7.html)
IL (3) IL188545A (cg-RX-API-DMAC7.html)
NL (1) NL301150I2 (cg-RX-API-DMAC7.html)
NZ (2) NZ565217A (cg-RX-API-DMAC7.html)
PL (4) PL3354273T3 (cg-RX-API-DMAC7.html)
PT (4) PT2286825T (cg-RX-API-DMAC7.html)
RU (2) RU2439079C2 (cg-RX-API-DMAC7.html)
SG (1) SG163585A1 (cg-RX-API-DMAC7.html)
SI (1) SI3354273T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007008704A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663916T3 (es) * 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2979703B1 (en) * 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
EP2297178B1 (en) 2008-05-27 2014-07-30 Genzyme Corporation Peptide analogs of alpha-melanocyte stimulating hormone
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
BRPI1009644B1 (pt) 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
MX2012001513A (es) * 2009-08-05 2012-05-22 Ipsen Pharma Sas Uso de melanocortinas para tratar la dislipidemia.
ES2624451T3 (es) * 2009-08-31 2017-07-14 Tensive Controls, Inc. Ligandos de melanocortina estabilizados
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
WO2011060355A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
KR102038677B1 (ko) * 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
WO2014060606A1 (en) * 2012-10-19 2014-04-24 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2014153221A2 (en) 2013-03-14 2014-09-25 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
MX2018003983A (es) 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US10653743B2 (en) * 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US20200223889A1 (en) * 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2019219714A1 (en) * 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
CA3100868A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
JP2023542985A (ja) * 2020-09-24 2023-10-12 リズム ファーマシューティカルズ, インコーポレイテッド メラノコルチン-4受容体経路関連障害の治療方法
CA3213099A1 (en) * 2021-03-24 2022-09-29 Robert A. Love Peptides and methods for reducing skin pigmentation
JP2024522348A (ja) * 2021-05-27 2024-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Mc3rアゴニストペプチド
US20260103529A1 (en) 2022-10-18 2026-04-16 Confo Therapeutics N.V. Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders
WO2025123056A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods
WO2025245288A1 (en) * 2024-05-22 2025-11-27 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof
CN120699097B (zh) * 2024-09-03 2026-06-12 万邦德制药集团有限公司 一种二硫环肽化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
AU7464998A (en) 1997-10-27 1999-05-17 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6127381A (en) * 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
AU758179B2 (en) * 1998-07-27 2003-03-20 Iowa State University Research Foundation Inc. Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
WO2000010507A2 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
HK1044954B (en) * 1999-03-29 2008-11-21 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6639123B1 (en) 1999-11-12 2003-10-28 Merck & Co., Inc. Melanocortin-3 receptor deficient cells, non-human trangenic animals and methods of selecting compounds which regulate body weight
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
BR0111567A (pt) * 2000-06-28 2003-05-06 Pfizer Prod Inc Ligandos do receptor de melanocortina
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US6689938B2 (en) 2000-09-13 2004-02-10 Oklajoma Medical Research Foundation Method for treatment of insulin resistance in obesity and diabetes
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
EP1363898A4 (en) 2001-03-02 2004-12-08 Bristol Myers Squibb Co COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
EA200600055A1 (ru) * 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1658273B1 (en) 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ES2286679T3 (es) 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
EP1732586A1 (en) 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
NZ554427A (en) 2004-10-08 2010-09-30 Clinuvel Pharmaceuticals Ltd Compositions and methods for inducing melanogenesis in a subject utilising afamelanotide
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
ES2663916T3 (es) * 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
ES2407107T3 (es) 2005-08-26 2013-06-11 Abbvie Inc. Análogos de alfa-MSH terapéuticamente activos

Similar Documents

Publication Publication Date Title
RU2401841C2 (ru) Лиганды рецепторов меланокортинов
RU2009131092A (ru) Лиганды рецепторов меланокортинов
JP2009500427A5 (cg-RX-API-DMAC7.html)
CA2689016A1 (en) Melanocortin receptor ligands modified with hydantoin
KR101226165B1 (ko) 피부 외용제 조성물
US6262021B1 (en) Use of substances having oxytocin activity for preparation of medicaments for wound healing
TWI619505B (zh) 脫毛症治療劑
TWI374030B (en) Use of melanocortins to treat insulin sensitivity
JP2021102650A5 (cg-RX-API-DMAC7.html)
TW201601743A (zh) 外周kappa鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途
RU2012136530A (ru) Новые соединения, влияющие на пищевое поведение
CN108135965B (zh) 用于伤口愈合的含p物质的药物组合物
Lippert et al. Effects of oxytocin outside pregnancy
RU2012106302A (ru) Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
JP6800372B2 (ja) 持続型パルミチン酸結合GnRH誘導体及びこれを含む薬剤学的組成物
Stern Nursing posture is elicited rapidly in maternally naive, haloperidol-treated female and male rats in response to ventral trunk stimulation from active pups
Rukhliada et al. The characteristics of pharmacokinetics and the biological effects of gonadotropin-releasing hormone agonists
CN101848927A (zh) 镇痛化合物
CN102631663B (zh) 一种治疗男性不育、阳痿早泄的制剂及其应用
CN110935007B (zh) 利那洛肽复方组合物、制剂及其用途和制备方法
CN115381955A (zh) 黑皮质素受体mc5r的用途
WO2017088177A1 (zh) 贻贝粘蛋白产品及其预防和抑制神经炎症的应用
US20120142601A1 (en) Modified Peptides and Uses Thereof
KAWAKAMI Electro-myographic study of the human abdominal muscles affected by sexual hormones
RU2761050C1 (ru) Способ восстановления половой цикличности и плодовитости коров при гипофункции яичников